Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

Key Takeaway: Enanta Pharmaceuticals has announced progress in its clinical development program for Zelicapavir, aimed at treating Respiratory Syncytial Virus (RSV). The announcement highlights the company's ongoing efforts in addressing this viral infection. Further details on the program's advancements were not provided in the article.